GLP-1 Medications and PCOS: What the Research Actually Shows

PCOS is one of the most under-treated conditions in women's medicine. Despite affecting approximately one in ten UK women of reproductive age, the standard of care has changed remarkably little in decades: the combined oral contraceptive pill for symptom management, metformin for insulin resistance, and lifestyle advice that, while correct, is extraordinarily difficult to follow when the hormonal environment of PCOS is actively working against weight loss.

GLP-1 medications represent a genuinely different approach. Not because they are a cure. They are not. But because they target the metabolic mechanism that drives PCOS features in most women, rather than managing symptoms individually.

Here is what the evidence actually shows, including where it is strong and where it is still developing.

The Central Role of Insulin Resistance in PCOS

PCOS is defined by the Rotterdam criteria: two of three features, namely irregular or absent periods, biochemical or clinical hyperandrogenism (excess androgens), and polycystic ovarian morphology on ultrasound. However, this symptom-based definition does not capture the metabolic core of the condition.

Approximately 65 to 80% of women with PCOS have insulin resistance, including a significant proportion who are of normal weight. Hyperinsulinaemia (excess circulating insulin, a consequence of cells failing to respond properly) is not merely a side effect of PCOS. For most women, it is a central driver.

Excess insulin does several things that are directly relevant to PCOS features:

• Stimulates the ovaries to produce excess androgens, particularly testosterone and androstenedione
• Reduces sex hormone-binding globulin (SHBG), increasing the proportion of testosterone that is biologically active (free testosterone)
• Disrupts the LH/FSH hormone ratio, impairing regular ovulation
• Promotes visceral fat accumulation, which further worsens insulin resistance

The result is a self-reinforcing cycle. Insulin resistance worsens PCOS features, which promote further metabolic dysfunction, which deepens insulin resistance. This is why treatments that address only individual symptoms (the pill for periods, topical treatment for acne, laser for hirsutism) often feel inadequate. They do not interrupt the underlying cycle.

How GLP-1 Medications Address the Cycle

GLP-1 receptor agonists improve insulin sensitivity through several mechanisms that are directly relevant to PCOS:

Glucose-dependent insulin secretion: GLP-1 stimulates insulin release from pancreatic beta cells only when blood glucose is elevated. This improves the dysregulated insulin response without causing hypoglycaemia.

Fasting insulin reduction: As weight loss on GLP-1 treatment reduces visceral fat (a major source of inflammatory cytokines that impair insulin signalling), fasting insulin levels typically fall significantly. This reduces the chronic ovarian androgen stimulation that fasting hyperinsulinaemia causes.

Appetite regulation: The reduced calorie intake that accompanies GLP-1 treatment breaks the cycle of weight gain that worsens insulin resistance, in a way that lifestyle modification alone frequently cannot achieve in the PCOS hormonal environment.

Possible direct ovarian effects: Some early research has identified GLP-1 receptors in ovarian granulosa cells, suggesting potential direct effects on ovarian function independent of insulin and weight changes. This remains an active area of investigation and should not be overstated based on current evidence.

What the Clinical Trials Actually Show

The research base for GLP-1 medications specifically in PCOS is growing steadily, though it is not yet at the scale of the major diabetes and obesity trials.

A 2023 systematic review and meta-analysis examining GLP-1 receptor agonists specifically in PCOS identified consistent improvements across studies in:

• Free androgen index (reduced in all studies reviewed)
• Total and free testosterone levels
• HOMA-IR (insulin resistance marker): meaningful improvement in the majority of studies
• BMI and waist circumference: greater reductions than metformin comparators in most head-to-head analyses
• Menstrual regularity: improvements documented in the majority of studies, with a subset achieving regular cycles after prolonged amenorrhoea

GLP-1 vs Metformin for PCOS

Metformin is the most widely prescribed medication for insulin resistance in PCOS. It is inexpensive, familiar to GPs, and effective in a subset of patients. However, its effects on weight are modest, its tolerability is variable (GI side effects cause many women to reduce dose or discontinue), and its impact on androgen levels is less pronounced than its impact on glucose metabolism.

The direct comparison evidence favours GLP-1 medications on most PCOS-relevant outcomes. This does not mean metformin has no role: for women who tolerate it and respond to it, it remains a reasonable, low-cost option. Some evidence suggests combining metformin and a GLP-1 medication produces additive benefits. This is a conversation to have with a prescriber.

Menstrual Regularity and Ovulatory Function

One of the most striking findings in PCOS GLP-1 research is the frequency of menstrual cycle normalisation during treatment. Women who have had irregular or absent periods for years, some of whom have been told their cycles will not regulate without hormonal contraception, report cycle restoration on semaglutide.

This is not universal. But it is documented consistently enough across multiple trials to be clinically meaningful.

The mechanism is understood: as fasting insulin falls and androgen levels reduce, the LH/FSH ratio normalises, follicular development improves, and ovulation can occur.

What This Means for Fertility

The improvement in ovulatory function documented in PCOS GLP-1 trials has important implications for fertility, and they cut in both directions.

For women with PCOS who are trying to conceive and who have not responded adequately to standard fertility treatments, the improvement in insulin resistance and ovulatory function that GLP-1 medications produce may be beneficial. Some fertility specialists are incorporating GLP-1 medications into pre-conception preparation for women with PCOS, particularly those with significant insulin resistance.

However, GLP-1 medications are not licensed fertility treatments. Current regulatory guidance from Novo Nordisk and prescribing guidance from specialist bodies recommends stopping semaglutide and tirzepatide at least two months before attempting to conceive. There are insufficient human safety data on these medications during pregnancy to support continuation.

The fertility implication that catches many women off guard is in the other direction: GLP-1 medications are not contraceptives, and women who had been told they were unlikely to conceive due to PCOS should not assume this remains true once on treatment. Effective contraception is essential if pregnancy is not intended.

For more on PCOS and reproductive health, see the companion article on GLP-1 medications and PCOS treatment in the UK.

Who Can Get GLP-1 Prescribed for PCOS in the UK?

Currently, GLP-1 medications for PCOS in the UK are prescribed almost exclusively through private channels. This includes private endocrinologists, private GPs, and online weight management clinics that take a full medical history and assess PCOS features.

NHS prescribing of GLP-1 medications remains tied to licensed indications: type 2 diabetes (Ozempic, Mounjaro) and obesity meeting specific BMI criteria (Wegovy, with Mounjaro emerging). PCOS alone is not a listed NHS indication.

For women with PCOS who also meet BMI criteria for obesity treatment (BMI 35+ with a weight-related condition, or BMI 40+), accessing the NHS weight management pathway remains a possibility. This would result in a GLP-1 prescription for the obesity indication, with PCOS features potentially improving as a consequence. See NHS Wegovy eligibility in 2026 for current criteria and realistic waiting times.

Monitoring on GLP-1 Treatment for PCOS

If you are taking a GLP-1 medication for PCOS, or considering doing so, baseline and follow-up blood tests are essential. A good prescriber will arrange these, but it is useful to know what to ask for.

At baseline:

• Total testosterone, free testosterone, SHBG, free androgen index
• LH, FSH, oestradiol (ideally day 2 to 4 of cycle, or randomly if cycles are absent)
• Fasting glucose and insulin, HOMA-IR where available
• Full blood count, thyroid function (TSH, free T4), vitamin D, ferritin

At 3 and 6 months:

• Repeat androgens, SHBG, and insulin markers
• Weight and waist circumference
• Menstrual calendar (document cycle length, regularity, duration of bleed)

A women's health-focused clinic that understands PCOS is better positioned to monitor these than a generic weight loss programme.

For guidance on which blood tests to run before starting any GLP-1 medication, see blood tests before starting GLP-1.

Managing PCOS Symptoms Alongside GLP-1 Treatment

GLP-1 medications address the metabolic root of PCOS powerfully, but other aspects of management remain relevant during treatment:

Hirsutism: Androgen-driven hair growth responds slowly. Even with significant testosterone reduction, existing hair follicles that have been activated by androgens require 6 to 12 months to show improvement. Physical hair removal methods remain effective. Spironolactone and co-cyprindiol are medical options for women who need faster cosmetic improvement.

Acne: Androgen-related acne often improves as free testosterone falls, but the timeline varies. Topical treatments remain appropriate for active lesions while hormonal improvement takes effect.

Mental health: PCOS is associated with substantially elevated rates of anxiety and depression. The metabolic improvements from GLP-1 treatment may contribute to mood improvement, but this should not replace appropriate mental health support. See the guide on GLP-1 and mental health for what the evidence shows.

Nutritional considerations: The appetite suppression on GLP-1 medications can reduce overall food intake significantly. For women with PCOS, maintaining adequate protein intake is particularly important for muscle mass and hormonal health. Micronutrient deficiencies (iron, vitamin D, B12) are worth monitoring.

The Bottom Line

GLP-1 medications target insulin resistance, the metabolic driver at the centre of PCOS for most women. Clinical evidence consistently shows improvements in androgens, menstrual regularity, and insulin sensitivity. These are not peripheral outcomes. They are the outcomes that determine how PCOS affects day-to-day life.

The evidence is not yet at the scale required for a formal licensed indication in PCOS, and it may be some years before NHS prescribing reflects it. But the research quality is growing, and the clinical rationale is strong.

For women with PCOS who have been managing symptoms individually for years, with the pill, topical treatments, and diet advice, a conversation about GLP-1 medications with a knowledgeable prescriber is worth having.